Development and validation of the sickle cell stress scale-adult
- PMID: 35585659
- PMCID: PMC9531901
- DOI: 10.1111/ejh.13789
Development and validation of the sickle cell stress scale-adult
Abstract
Disease-specific stress can partly explain Sickle Cell Disease (SCD) healthcare utilization. We developed and validated two measures of adult SCD-specific stress for research and clinical care. A large cohort of adults with SCD completed both the 3-item Likert-scale adapted from a previous disease stress measure and a 10-item Likert-scale questionnaire drafted specifically to measure SCD stress. They concurrently completed a psychosocial and health-related quality of life scale battery, then subsequently daily pain diaries. Diaires measured: daily intensity, distress and interference of pain; self-defined vaso-occlusive crises (VOC), opioid use, and types of healthcare utilization for up to 24 weeks. Analyses tested Cronbach's alpha, correlation of the three-item and 10-item stress scales with the concurrent battery, with percentages of pain days, VOC days, opioid use days, and healthcare utilization days, and correlation of baseline stress and 6-month stress for the 10-item scale. Cronbach's alpha was high for both the 3-item (0.73) and 10-item (0.83) SCD stress scales, test-retest correlation of 0.55, expected correlation with the concurrent battery, and correlation with diary-measured healthcare utilization over 6 months. The correlations with the 3-item scale were stronger, but only statistically significant for depression-anxiety. The correlation between the two stress scales was 0.59. Both the 3-item and the 10-item stress scales exhibited good face, construct, concurrent, and predictive validity as well as moderate test-retest reliability. Further scale validation should determine population norms and response to interventions.
Keywords: assessment; coping; healthcare utilization; pain; sickle cell disease; stress.
© 2022 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.
Conflict of interest statement
During the time of this work, none of the co‐authors had any relevant conflicts of interest or appearances of conflict of interest.
Figures
References
MeSH terms
Substances
Grants and funding
- U10 HL083732/HL/NHLBI NIH HHS/United States
- U54 HL090516/HL/NHLBI NIH HHS/United States
- R01 HL064122/HL/NHLBI NIH HHS/United States
- R18 HL112737/HL/NHLBI NIH HHS/United States
- Pain in Sickle Cell Epidemiology Study, 1 R01 HL 64122, National Heart, Lung, and Blood Institute
- A.D. Williams Faculty Research Grant, Virginia Commonwealth University
- Virginia Basic and Translational Research Program in Sickle Cell Disease. 1U54HL090516, National Heart, Lung, and Blood Institute
- A.D. Williams Student Research Fellowships, Virgin ia Commonwealth University
- Enhancing Use of Hydroxyurea In Sickle Cell Disease Using Patient Navigators
- Clinical Research Training Program, National Institutes of Health
- Sickle Cell Disease Clinical Research Network, National Heart, Lung, and Blood Institute 1U10HL083732
- Robert Wood Johnson Foundation Generalist Physician Faculty Scholar Award (1993-1997)
- VCU School of Medicine Student Fellowships
- Enhancing Use of Hydroxyurea In Sickle Cell Disease Using Patient Navigators (NCT02197845, 1 R18 HL 112737, National Heart, Lung, and Blood Institute
LinkOut - more resources
Full Text Sources
Medical